Cargando…

The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy

BACKGROUND: Patients with Duchenne muscular dystrophy (DMD) develop cardiomyopathy because of a dystrophin deficiency causing fibrofatty replacement of the myocardium. Corticosteroid use and mobility limitations place these patients at risk for increased adiposity. We sought to determine the associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Henson, Sarah E., Lang, Sean M., Khoury, Philip R., Tian, Cuixia, Rutter, Meilan M., Urbina, Elaine M., Ryan, Thomas D., Taylor, Michael D., Alsaied, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649129/
https://www.ncbi.nlm.nih.gov/pubmed/34569261
http://dx.doi.org/10.1161/JAHA.121.021037
_version_ 1784610930946998272
author Henson, Sarah E.
Lang, Sean M.
Khoury, Philip R.
Tian, Cuixia
Rutter, Meilan M.
Urbina, Elaine M.
Ryan, Thomas D.
Taylor, Michael D.
Alsaied, Tarek
author_facet Henson, Sarah E.
Lang, Sean M.
Khoury, Philip R.
Tian, Cuixia
Rutter, Meilan M.
Urbina, Elaine M.
Ryan, Thomas D.
Taylor, Michael D.
Alsaied, Tarek
author_sort Henson, Sarah E.
collection PubMed
description BACKGROUND: Patients with Duchenne muscular dystrophy (DMD) develop cardiomyopathy because of a dystrophin deficiency causing fibrofatty replacement of the myocardium. Corticosteroid use and mobility limitations place these patients at risk for increased adiposity. We sought to determine the association of adiposity with cardiovascular dysfunction in patients with DMD. METHODS AND RESULTS: This was a retrospective review of patients with DMD who underwent both cardiac magnetic resonance imaging and dual‐energy x‐ray absorptiometry within 1 year. The cardiac magnetic resonance imaging parameters included left ventricular ejection fraction and the presence of late gadolinium enhancement (LGE positive [LGE+]). The adiposity indices, measured by dual‐energy x‐ray absorptiometry, included percentage of body fat, whole body fat mass indexed to height, and body mass index. A total of 324 patients were identified. Fifty‐two percent had LGE+, and 36% had cardiac dysfunction (left ventricular ejection fraction <55%). Patients with cardiac dysfunction had higher whole body fat mass indexed to height and body mass index on univariate analysis (mean difference between patients with and without cardiac dysfunction: +2.9 kg/m, P=0.001; and +1.5 kg/m(2), P=0.03, respectively). whole body fat mass indexed to height remained independently associated with cardiac dysfunction on multivariable analysis after adjusting for age, LGE+, and corticosteroid duration. High whole body fat mass indexed to height and percentage of body fat were associated with LGE+ on univariate analysis (mean difference between patients with and without LGE+: +2.0 kg/m, P=0.02; and +2.4%, P=0.02, respectively). Using multivariable analysis, including age and cardiac dysfunction, high percentage of body fat remained independently associated with LGE+. CONCLUSIONS: This study demonstrates an independent association of adiposity with cardiac dysfunction and LGE+ in patients with DMD. Preventing adiposity may mitigate the later development of ventricular dysfunction in DMD.
format Online
Article
Text
id pubmed-8649129
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-86491292022-03-21 The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy Henson, Sarah E. Lang, Sean M. Khoury, Philip R. Tian, Cuixia Rutter, Meilan M. Urbina, Elaine M. Ryan, Thomas D. Taylor, Michael D. Alsaied, Tarek J Am Heart Assoc Original Research BACKGROUND: Patients with Duchenne muscular dystrophy (DMD) develop cardiomyopathy because of a dystrophin deficiency causing fibrofatty replacement of the myocardium. Corticosteroid use and mobility limitations place these patients at risk for increased adiposity. We sought to determine the association of adiposity with cardiovascular dysfunction in patients with DMD. METHODS AND RESULTS: This was a retrospective review of patients with DMD who underwent both cardiac magnetic resonance imaging and dual‐energy x‐ray absorptiometry within 1 year. The cardiac magnetic resonance imaging parameters included left ventricular ejection fraction and the presence of late gadolinium enhancement (LGE positive [LGE+]). The adiposity indices, measured by dual‐energy x‐ray absorptiometry, included percentage of body fat, whole body fat mass indexed to height, and body mass index. A total of 324 patients were identified. Fifty‐two percent had LGE+, and 36% had cardiac dysfunction (left ventricular ejection fraction <55%). Patients with cardiac dysfunction had higher whole body fat mass indexed to height and body mass index on univariate analysis (mean difference between patients with and without cardiac dysfunction: +2.9 kg/m, P=0.001; and +1.5 kg/m(2), P=0.03, respectively). whole body fat mass indexed to height remained independently associated with cardiac dysfunction on multivariable analysis after adjusting for age, LGE+, and corticosteroid duration. High whole body fat mass indexed to height and percentage of body fat were associated with LGE+ on univariate analysis (mean difference between patients with and without LGE+: +2.0 kg/m, P=0.02; and +2.4%, P=0.02, respectively). Using multivariable analysis, including age and cardiac dysfunction, high percentage of body fat remained independently associated with LGE+. CONCLUSIONS: This study demonstrates an independent association of adiposity with cardiac dysfunction and LGE+ in patients with DMD. Preventing adiposity may mitigate the later development of ventricular dysfunction in DMD. John Wiley and Sons Inc. 2021-09-25 /pmc/articles/PMC8649129/ /pubmed/34569261 http://dx.doi.org/10.1161/JAHA.121.021037 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Henson, Sarah E.
Lang, Sean M.
Khoury, Philip R.
Tian, Cuixia
Rutter, Meilan M.
Urbina, Elaine M.
Ryan, Thomas D.
Taylor, Michael D.
Alsaied, Tarek
The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy
title The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy
title_full The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy
title_fullStr The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy
title_full_unstemmed The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy
title_short The Effect of Adiposity on Cardiovascular Function and Myocardial Fibrosis in Patients With Duchenne Muscular Dystrophy
title_sort effect of adiposity on cardiovascular function and myocardial fibrosis in patients with duchenne muscular dystrophy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649129/
https://www.ncbi.nlm.nih.gov/pubmed/34569261
http://dx.doi.org/10.1161/JAHA.121.021037
work_keys_str_mv AT hensonsarahe theeffectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT langseanm theeffectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT khouryphilipr theeffectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT tiancuixia theeffectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT ruttermeilanm theeffectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT urbinaelainem theeffectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT ryanthomasd theeffectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT taylormichaeld theeffectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT alsaiedtarek theeffectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT hensonsarahe effectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT langseanm effectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT khouryphilipr effectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT tiancuixia effectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT ruttermeilanm effectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT urbinaelainem effectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT ryanthomasd effectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT taylormichaeld effectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy
AT alsaiedtarek effectofadiposityoncardiovascularfunctionandmyocardialfibrosisinpatientswithduchennemusculardystrophy